InvestSMART

Pro Medicus Limited (ASX:PME)

ALERT: Price-sensitive ASX Announcement for PME
Current share price for PME : $163.920 -11.94 (-6.79%)+
Announcement
Release
18 Aug 2026 9:36AM
Price at Release
$175.860
Full Release
download
Summary
Pro Medicus Limited's FY26 results reflect a year in line with expectations, highlighted by significant revenue and profit growth, despite currency fluctuations impacting financials. The company achieved a substantial increase in new contracts and renewals, coupled with a strong performance in implementations. Pro Medicus continues to leverage AI and cloud technologies, with their Visage platform gaining traction in major US healthcare institutions. The introduction of a new cardiology module and digital pathology solution indicates a strategic expansion, while maintaining strong financial margins and a robust pipeline for future growth.
Key Points
  • FY26 results in line with expectations.
  • Strong growth in revenue and profit.
  • Currency fluctuations impacted financials.
  • Increase in new contracts and renewals.
  • Significant performance in implementations.
  • Leveraging AI and cloud technologies.
  • Visage platform used by major US healthcare institutions.
  • Introduction of cardiology module and digital pathology solution.
  • Strong financial margins maintained.
  • Robust pipeline for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.